Blackstone and TPG completed their acquisition of Hologic, moving the molecular diagnostics company off public markets at a valuation described as up to $18.3 billion. Under the deal, Hologic shareholders receive $76 per share in cash plus a contingent value right that can pay up to an additional $3 per share based on revenue goals for fiscal years 2026 and 2027. Hologic’s shares will stop trading and be delisted from Nasdaq. José Almeida was named CEO effective immediately, after serving as chairman, president, and CEO of Baxter International until 2025. The transaction brings breast and skeletal health products as well as molecular diagnostics platforms under private ownership, with Hologic citing plans to accelerate growth without public-market constraints. The deal underscores continued consolidation pressure across medtech and diagnostics.